Verastem promoted Robert Forrester to President in addition to COO. Verastem is planning multiple clinical trials for 2013 across its programs targeting FAK and PI3K/mTOR. The current clinical plans include a midyear initiation of a potentially pivotal trial in mesothelioma for lead FAK inhibitor, VS-6063.
- Politics & Government
- Pharmaceuticals & Drug Trials